Anthem Bioscienc Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹550Cr
- +4.8% YoY
- +1.9% QoQ
- Net profit
- ₹173Cr
- +6.8% YoY
- +27.2% QoQ
- Margin
- 40%
- +3 pp YoY
- +5 pp QoQ
Guidance rank: #66 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.
From Anthem Bioscienc's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance.
- Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes.
- Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually.
- Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong.
- Expansion projects (Unit-III and Unit-IV) and new capacities (e.g., 130 kiloliters added recently, Unit-IV with 400 kiloliters planned) aim to support increased volumes and revenues.
2 more points from Anthem Bioscienc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).
- Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward.
- Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr.
- Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV.
2 more points from Anthem Bioscienc's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline.
- The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years.
- The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution.
2 more points from Anthem Bioscienc's call on order book
Create a free account to keep reading this call
Anthem Bioscienc — Quarterly revenue & net profit
Anthem Bioscienc Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 550 | 525 | +4.8% | 540 | +1.9% |
| Operating profit (EBITDA) | 218 | 195 | +11.8% | 191 | +14.1% |
| Operating margin | 40% | 37% | +3 pp | 35% | +5 pp |
| Profit before tax | 230 | 200 | +15% | 186 | +23.7% |
| Net profit (PAT) | 173 | 162 | +6.8% | 136 | +27.2% |
| EPS (₹) | 3.09 | 2.90 | +6.6% | 2.42 | +27.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹594 Cr, net profit ₹211 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anthem Bioscienc's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anthem Bioscienc and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anthem Bioscienc Q2 FY26 results?
Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.
What is Anthem Bioscienc share price analysis?
Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anthem Bioscienc planning capital expenditure?
Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).
Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
